Aware of the high expectations associated with the first birth control in terms of accessibility, simplicity and efficiency, and leveraging its expertise in gynecology, laboratory Théramex, today announced the launch of a website dedicated public information and support for young girls who start oral contraceptives: mapremierepilule.com
The laboratory Théramex, company division Merck Serono (Merck KGaA, Darmstadt, Germany), today announced the launch of a website dedicated to consumer information and support for young girls who start a contraceptive oral www.mapremierepilule.com
While France is characterized by widespread dissemination of birth control first and foremost oral contraception, the number of voluntary termination of pregnancy (abortion) remains high. Thus the 220,000 abortions that occur each year in France, 22,000 are directly related to an oversight pilule1. Misinformation and misconceptions that persist about the pill, and its cost and non-repayment of some of them could constitute obstacles to its proper use and generate compliance problems. In this context, mapremierepilule.com, site for young girls who are starting a contraceptive pill, is designed to provide answers to questions and concerns that may have the girls who take the pill for the first time. The purpose of this site is to inform and guide teens who may feel a little lost when they want access to contraception.
No comments:
Post a Comment